Industrials

Key opportunities in the psychedelic drugs market include rising demand for mental health treatments, especially for conditions like depression and PTSD. Advances in clinical trials and regulatory support enhance acceptance, while integration with digital health tools augments care. Global policy reforms and decriminalization further bolster growth prospects.

The Saudi Arabia Generic Drugs Market is projected to expand from US$ 4.05 billion in 2024 to US$ 8.11 billion by 2033, registering a CAGR of 8.02%. This growth is driven by increased healthcare needs, government initiatives to reduce pharmaceutical spending, and rising awareness of affordable alternatives. Supportive regulatory policies by the Saudi Food and Drug Authority (SFDA) and investments in local manufacturing are further spurring market expansion. The market is also bolstered by growing demand due to the rising prevalence of chronic diseases and increased acceptance among consumers and healthcare professionals.

KN invites shareholders, investors, analysts, and other stakeholders to join its investor conference webinar scheduled on August 22^nd of 2025 at 9.00 am (EET). The presentation will be held in English.

Š. m. rugpjūčio 22 d. 9.00 val. KN kviečia akcininkus, investuotojus, analitikus ir visus besidominčius į 2025 metų šešių mėnesių neaudituotų finansinių rezultatų pristatymą internetiniame seminare (angl. „webinar“), kuris vyks anglų kalba.

Secures Access to Liquidity and Financial Flexibility

SINGAPORE, Aug. 13, 2025 (GLOBE NEWSWIRE) -- August 13, 2025 – Magnitude International Ltd (the “Company” or “Magnitude”) (Nasdaq: MAGH), an electrical installation service provider based in Singapore, today announced the closing of its initial public offering (the “Offering”) of 2,200,000 ordinary shares at a public offering price of US$4.00 per ordinary share for total gross proceeds of US$8.8 million, before deducting underwriting discounts and offering expenses. The Company sold 1,650,000 ordinary shares and a selling shareholder, XJL International Ltd, sold 550,000 ordinary shares. The Company did not receive any proceeds from the sale of ordinary shares by the selling shareholder.